Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 2
2018 8
2019 20
2020 18
2021 10
2022 15
2023 14
2024 15
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 40037864

101 results

Results by year

Filters applied: . Clear all
Page 1
Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Kodama H, Kadowaki S, Ishizuka Y, Wakabayashi M, Sakakida T, Honda K, Masuishi T, Narita Y, Taniguchi H, Ando M, Kishikawa T, Terada H, Beppu S, Nishikawa D, Suzuki H, Hanai N, Muro K. Kodama H, et al. Int J Clin Oncol. 2025 Mar;30(3):480-488. doi: 10.1007/s10147-025-02698-1. Epub 2025 Jan 14. Int J Clin Oncol. 2025. PMID: 39806030
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258
Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study.
Rutkowski TW, Kurczyk A, Drosik-Rutowicz K, Kiprian D, Dębicka I, Sierko E, Konopka-Filippow M, Kaźmierska J, Łukasiewicz-Grella M, Cząstkiewicz-Trawińska D, Mrochem-Domin I, Ryniewicz-Zander I, Borysiewicz Z, Chmielowska E, Jasiówka M, Źrebiec-Figura M, Karpińska A, Pacholczak-Madej R, Leś D, Pietruszka A, Łasinska I, Składowski K. Rutkowski TW, et al. Int J Cancer. 2025 Mar 1;156(5):1074-1084. doi: 10.1002/ijc.35248. Epub 2024 Nov 5. Int J Cancer. 2025. PMID: 39501482 Free PMC article.
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Ferris RL, et al. Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25. Clin Cancer Res. 2019. PMID: 31239321 Free PMC article. Clinical Trial.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, Anderson AM, Ekpenyong A, Rupji M, Abousaud M, Rudra S, Bates JE, Remick JS, Joshi NP, Woody NM, Awan M, Geiger JL, Shreenivas A, Samsa J, Ward MC, Schmitt NC, Patel MR, Higgins KA, Teng Y, Steuer CE, Shin DM, Liu Y, Ahmed R, Koyfman SA. Saba NF, et al. JAMA Oncol. 2024 Jul 1;10(7):896-904. doi: 10.1001/jamaoncol.2024.1143. JAMA Oncol. 2024. PMID: 38780927 Clinical Trial.
101 results